Properties of protein drug target classes

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bull, Simon C ^a   Doig, Andrew J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINE; ASPARTIC ACID; CYSTEINE; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GLUTAMIC ACID; HISTIDINE; IMATINIB; ION CHANNEL; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; PROLINE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEINASE; SERINE; SUNITINIB; THREONINE; TRYPTOPHAN; TUMOR PROTEIN; TYROSINE; VALINE; PEPTIDE HYDROLASE; PHOSPHOTRANSFERASE; PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALPHA HELIX; AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; EXPRESSED SEQUENCE TAG; GERMLINE MUTATION; HUMAN; HYDROPHOBICITY; ISOELECTRIC POINT; MACHINE LEARNING; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING; RANDOM FOREST; SIGNAL TRANSDUCTION; AGONISTS; ALGORITHM; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMISTRY; CLASSIFICATION; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN DATABASE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; ION CHANNELS; MOLECULAR TARGETED THERAPY; PEPTIDE HYDROLASES; PHOSPHOTRANSFERASES; PROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84926646390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117955     Document Type: Article

References (68)

1. Hopkins AL, Groom CR (2002) The druggable genome. Nature Rev Drug Discovery 1: 727-730.
2. Xu H, Xu HY, Lin MZ, Wang W, Li ZM, et al. (2007) Learning the drug target-likeness of a protein. Proteomics 7: 4255-4263. PMID: 17963289
3. Chen XP, Du GH (2007) Target validation: A door to drug discovery. Drug discoveries & therapeutics 1: 23-29.
4. Drews J (2000) Drug discovery: A historical perspective. Science 287: 1960-1964. PMID: 10720314
5. Imming P, Sinning S, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5: 821-834. PMID: 17016423
6. Overington J, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996. PMID: 17139284
7. Rask-Andersen M, Almen MS, Schioth HB (2011) Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery 10: 579-590. doi: 10.1038/nrd3478 PMID: 21804595
8. Russ AP, Lampel S (2005) The druggable genome: an update. Drug Discovery Today 10: 1607-1610. PMID: 16376820
9. Bakheet TM, Doig AJ (2009) Properties and identification of human protein drug targets. Bioinformatics 25: 451-457. doi: 10.1093/bioinformatics/btp002 PMID: 19164304
10. Zheng CJ, Han LY, Yap CW, Ji ZL, Cao ZW, et al. (2006) Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics. Pharmacol Rev 58: 259-279. PMID: 16714488
11. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272. PMID: 12761335
12. Apweiler R, Martin MJ, O'Donovan C, Magrane M, Alam-Faruque Y, et al. (2010) The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Research 38: D142-D148. doi: 10.1093/nar/gkp846 PMID: 19843607
13. Gerber DE (2008) Targeted therapies: A new generation of cancer treatments. American Family Physician 77: 311-319. PMID: 18297955
14. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123. PMID: 12086869
15. Harley CB (2008) Telomerase and cancer therapeutics. Nature Reviews Cancer 8: 167-179. doi: 10.1038/nrc2275 PMID: 18256617
16. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974. PMID: 16355214
17. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. Journal of Pharmacology and Experimental Therapeutics 315: 971-979. PMID: 16002463
18. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nature Reviews Cancer 7: 79-94. PMID: 17251915
19. Lane JR, Abdul-Ridha A, Canals M (2013) Regulation of G Protein-Coupled Receptors by Allosteric Ligands. Acs Chemical Neuroscience 4: 527-534. doi: 10.1021/cn400005t PMID: 23398684
20. May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annual Review of Pharmacology and Toxicology. Palo Alto: Annual Reviews. pp. 1-51. PMID: 17009927
21. Cavanaugh A, Huang Y, Breitwieser GE (2012) Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors. British Journal of Pharmacology 165: 1670-1677. doi: 10.1111/j.1476-5381.2011.01403.x PMID: 21470201
22. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nature Reviews Drug Discovery 1: 198-210. PMID: 12120504
23. Ashcroft FM (2006) From molecule to malady. Nature 440: 440-447. PMID: 16554803
24. Bagal S, Brown AD, Cox PJ, Omoto K, Owen RM, et al. (2013) Ion Channels as Therapeutic Targets: A Drug Discovery Perspective. Journal of Medicinal Chemistry 56: 593-624. doi: 10.1021/jm3011433 PMID: 23121096
25. Andersen OS (2008) Perspectives on how to drug an ion channel. Journal of General Physiology 131: 395-397. doi: 10.1085/jgp.200810012 PMID: 18411334
26. Dilly S, Lamy C, Marrion NV, Liegeois JF, Seutin V (2011) Ion-Channel Modulators: More Diversity Than Previously Thought. Chembiochem 12: 1808-1812. doi: 10.1002/cbic.201100236 PMID: 21726033
27. McNulty MM, Edgerton GB, Shah RD, Hanck DA, Fozzard HA, et al. (2007) Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels. Journal of Physiology-London 581: 741-755. PMID: 17363383
28. Borjesson SI, Parkkari T, Hammarstrom S, Elinder F (2010) Electrostatic Tuning of Cellular Excitability. Biophysical Journal 98: 396-403. doi: 10.1016/j.bpj.2009.10.026 PMID: 20141752
29. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912-+. PMID: 12471243
30. Hanks SK, Hunter T (1995) Protein Kinases. 6. the Eukaryotic Protein-Kinase Superfamily - Kinase (Catalytic) Domain-Structure and Classification. Faseb Journal 9: 576-596. PMID: 7768349
31. Engh RA, Bossemeyer D (2002) Structural aspects of protein kinase control - role of conformational flexibility. Pharmacology & Therapeutics 93: 99-111.
32. Garuti L, Roberti M, Bottegoni G (2010) Non-ATP Competitive Protein Kinase Inhibitors. Current Medicinal Chemistry 17: 2804-2821. PMID: 20586715
33. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology 2: 358-364. PMID: 16783341
34. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, et al. (2006) A Src-like inactive conformation in the Abl tyrosine kinase domain. Plos Biology 4: 753-767.
35. Noble MEM, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: Insights into drug design from structure. Science 303: 1800-1805. PMID: 15031492
36. Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nature Reviews Drug Discovery 9: 690-701. doi: 10.1038/nrd3053 PMID: 20811381
37. Turk B (2006) Targeting proteases: successes, failures and future prospects. Nature Reviews Drug Discovery 5: 785-799. PMID: 16955069
38. Shen A (2010) Allosteric regulation of protease activity by small molecules. Molecular Biosystems 6: 1431-1443. doi: 10.1039/c003913f PMID: 20539873
39. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, et al. (2009) BLAST plus: architecture and applications. Bmc Bioinformatics 10: 9. doi: 10.1186/1471-2105-10-9 PMID: 19128508
40. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157: 105-132. PMID: 7108955
41. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nature Reviews Cancer 4: 177-183. PMID: 14993899
42. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Research 39: D1035-D1041. doi: 10.1093/nar/gkq1126 PMID: 21059682
43. Zhu F, Han BC, Kumar P, Liu XH, Ma XH, et al. (2010) Update of TTD: Therapeutic Target Database. Nucleic Acids Research 38: D787-D791. doi: 10.1093/nar/gkp1014 PMID: 19933260
44. Petersen B, Petersen TN, Andersen P, Nielsen M, Lundegaard C (2009) A generic method for assignment of reliability scores applied to solvent accessibility predictions. Bmc Structural Biology 9: 10. doi: 10.1186/1472-6807-9-10 PMID: 19261183
45. Flicek P, Amode MR, Barrell D, Beal K, Brent S, et al. (2012) Ensembl 2012. Nucleic Acids Research 40: D84-D90. doi: 10.1093/nar/gkr991 PMID: 22086963
46. Kinsella RJ, Kahari A, Haider S, Zamora J, Proctor G, et al. (2011) Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database-the Journal of Biological Databases and Curation: 9. doi: 10.1093/database/bar013 PMID: 21498548
47. Wheeler DL, Church DM, Federhen S, Lash AE, Madden TL, et al. (2003) Database resources of the National Center for Biotechnology. Nucleic Acids Research 31: 28-33. PMID: 12519941
48. Eshelman LJ (1991) The CHC Adaptive Search Algorithm: How to Have Safe Search When Engaging in Nontraditional Genetic Recombination. In: Rawlings JE, editor. Foundations of Genetic Algorithms: Morgan Kaufmann. pp. 265-283.
49. McGraw KO, Wong SP (1992) A Common Language Effect Size Statistic. Psychological Bulletin 111: 361-365.
50. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA (2014) Emerging principles for the therapeutic exploitation of glycosylation. Science 343: 1235681. doi: 10.1126/science.1235681 PMID: 24385630
51. Helenius A, Aebi M (2004) Roles of N-linked glycans in the endoplasmic reticulum. Annual Review of Biochemistry 73: 1019-1049. PMID: 15189166
52. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, et al. (2014) Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Research 42: D199-D205. doi: 10.1093/nar/gkt1076 PMID: 24214961
53. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, et al. (2014) The Reactome pathway knowledgebase. Nucleic Acids Research 42: D472-D477. doi: 10.1093/nar/gkt1102 PMID: 24243840
54. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Research 37: D412-D416. doi: 10.1093/nar/gkn760 PMID: 18940858
55. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene Ontology: tool for the unification of biology. Nat Genet 25: 25-29. PMID: 10802651
56. Huang W, Sherman BT, Tan Q, Kir J, Liu D, et al. (2007) DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: 169-175.
57. Rogers S, Wells R, Rechsteiner M (1986) Amino-Acid-Sequences Common to Rapidly Degraded Proteins - the Pest Hypothesis. Science 234: 364-368. PMID: 2876518
58. Chatterjee S, Pal JK (2009) Role of 5′- and 3′-untranslated regions of mRNAs in human diseases. Biology of the Cell 101: 251-262. doi: 10.1042/BC20080104 PMID: 19275763
59. Coletta A, Pinney JW, Solis DYW, Marsh J, Pettifer SR, et al. (2010) Low-complexity regions within protein sequences have position-dependent roles. Bmc Systems Biology 4: 13. doi: 10.1186/1752-0509-4-13 PMID: 20181238
60. Dosztanyi Z, Chen J, Dunker AK, Simon I, Tompa P (2006) Disorder and sequence repeats in hub proteins and their implications for network evolution. Journal of Proteome Research 5: 2985-2995. PMID: 17081050
61. Ekman D, Light S, Bjorklund AK, Elofsson A (2006) What properties characterize the hub proteins of the protein-protein interaction network of Saccharomyces cerevisiae? Genome Biology 7: 13.
62. Romero P, Obradovic Z, Dunker AK (2004) Natively disordered proteins: functions and predictions. Appl Bioinformatics 3: 105-113. PMID: 15693736
63. Regard JB, Sato IT, Coughlin SR (2008) Anatomical Profiling of G Protein-Coupled Receptor Expression. Cell 135: 561-571. doi: 10.1016/j.cell.2008.08.040 PMID: 18984166
64. Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R (2004) Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene 330: 101-114. PMID: 15087129
65. Xu H, Collins JF, Bai LQ, Kiela PR, Ghishan FK (2001) Regulation of the human sodium-phosphate cotransporter NaPi-IIb gene promoter by epidermal growth factor. American Journal of Physiology-Cell Physiology 280: C628-C636. PMID: 11171583
66. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, et al. (2013) Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. International Journal of Cancer 132: 807-812. doi: 10.1002/ijc.27733 PMID: 22821757
67. Yin M, Dhir R, Parwani AV (2007) Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagnostic Pathology 2: 7. PMID: 17324277
68. Bull SC, Muldoon MR, Doig AJ (2013) Maximising the Size of Non-Redundant Protein Datasets Using Graph Theory. Plos One 8: 12.